Preclinical data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα, strongly inhibits pAKT signaling in tumor cells without inducing hyperglycemia, and shows robust anti-tumor activity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback